B
BDTX icon

Bailard’s Black Diamond Therapeutics BDTX Stock Holding History

Bailard’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-51,500
Closed -$110K – 769
2026
Q1 		$110K Buy
+51,500
New +$122K ﹤0.01% 724
2025
Q3 		– Sell
-15,800
Closed -$39.2K – 790
2025
Q2 		$39.2K Buy
+15,800
New +$30.5K ﹤0.01% 753
2022
Q4 		– Sell
-21,281
Closed -$36K – 712
2022
Q3 		$36K Sell
21,281
-37,219
-64% -$115K ﹤0.01% 653
2022
Q2 		$144K Buy
+58,500
New +$136K 0.01% 637

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Bailard's BDTX Position: Q2 2026 in Review

Bailard sold out of Black Diamond Therapeutics (BDTX) in Q2 2026, closing a stake of 51,500 shares — an estimated $110K sold.

Bailard first reported a position in BDTX in Q2 2022 and held it in 4 quarters. The position peaked at $144K in Q2 2022. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

  • Bailard reported no remaining Black Diamond Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Bailard sold 51,500 Black Diamond Therapeutics shares in Q2 2026, an estimated $110K.
  • Bailard first reported a position in Black Diamond Therapeutics in Q2 2022 and held it in 4 quarters.
  • Bailard's Black Diamond Therapeutics position peaked at $144K in Q2 2022.
  • 96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on Bailard's 13F filing for Q2 2026, filed 30 Jul 2026.